Form 4: BioLife Solutions EVP Sells Shares for Tax Obligations

BioLife Solutions' EVP & Chief Scientific Officer, Aby J. Mathew, sold 630 shares of common stock for $26.83 per share to cover tax withholding obligations.

Summary

• Aby J. Mathew, Executive Vice President & Chief Scientific Officer of BioLife Solutions Inc. (BLFS), reported a sale of common stock.
• The transaction involved the disposition of 630 shares of common stock.
• The shares were sold at a price of $26.83 per share.
• The sale occurred on September 11, 2025.
• Following this transaction, Aby J. Mathew beneficially owns 351,421 shares of common stock.
• The sale was executed pursuant to a Rule 10b5-1(c) trading plan, which was adopted on March 8, 2024.
• The purpose of the sale was to satisfy tax withholding obligations related to the vesting of restricted stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. This is a routine, pre-planned transaction by an executive to cover tax obligations related to vested equity, not indicative of a change in management's outlook or company fundamentals.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This specific insider transaction is a routine event for executives managing their equity compensation and tax liabilities, and it does not inherently reflect broader industry trends or competitive positioning for BioLife Solutions within the life sciences or biopreservation sectors.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a small, routine, and pre-planned sale for tax purposes by an executive, not signaling a change in company fundamentals or executive confidence.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The transaction reported is a routine, pre-planned sale by an executive to cover tax withholding obligations associated with vested restricted stock. It does not reflect a discretionary decision based on a change in the executive's view of the company's prospects or financial health. Therefore, it provides no new information that would warrant a change in investment recommendation for BioLife Solutions. Investors should maintain their current position based on the company's fundamental performance and broader market conditions.

Keywords

BioLife Solutions, BLFS, Insider Trading, Form 4, Stock Sale, Executive Compensation, Tax Withholding, Rule 10b5-1